Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric Cancer
The purpose of this study is to evaluate the efficacy and safety of sintilimab+ IBI310 for EBV-Positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
DRUG: Sintilimab|DRUG: IBI310
Arms 1: Neoadjuvant therapy group, Pathological complete regression (pCR):

Pathological complete regression (pCR) is defined as the proportion of patients with pathological complete regression (TRG1a) over the total number of patients evaluated centrally by the study pathologist, Approximately 40 months after the first participant is randomized|Arms 2: first-line therapy group, Objective response rate(ORR):

Objective response rate(ORR) of Sintilimab in combination with IBI310 in all participants in this group., Approximately 40 months after the first participant is randomized|Arms 3:≥second-line therapy group, Objective response rate(ORR):

Objective response rate(ORR) of Sintilimab in combination with IBI310 in all participants in this group., Approximately 40 months after the first participant is randomized
Arms 1: Neoadjuvant therapy group, R0 resection rate, Approximately 40 months after the first participant is randomized|Arms 1: Neoadjuvant therapy group, Event free survival(EFS), Approximately 40 months after the first participant is randomized|Arms 1: Neoadjuvant therapy group, Objective response rate(ORR), Approximately 40 months after the first participant is randomized|Arms 1: Neoadjuvant therapy group, Disease control rate(DCR), Approximately 40 months after the first participant is randomized|Arms 1: Neoadjuvant therapy group, Overall survival(OS), Approximately 40 months after the first participant is randomized|Arms 1: Neoadjuvant therapy group, Number of participants experiencing clinical and laboratory adverse events (AEs)., Approximately 40 months after the first participant is randomized|Arms 2: first-line therapy group, Progression-free survival (PFS）, Approximately 40 months after the first participant is randomized|Arms 2: first-line therapy group, Disease control rate (DCR）, Approximately 40 months after the first participant is randomized|Arms 2: first-line therapy group, Overall survival (OS）, Approximately 40 months after the first participant is randomized|Arms 2: first-line therapy group, ( Number of participants experiencing clinical and laboratory adverse events (AEs)., Approximately 40 months after the first participant is randomized|Arms 3:≥second-line therapy group, Progression-free survival (PFS）, Approximately 40 months after the first participant is randomized|Arms 3:≥second-line therapy group, Disease control rate (DCR), Approximately 40 months after the first participant is randomized|Arms 3:≥second-line therapy group, Overall survival (OS）, Approximately 40 months after the first participant is randomized|Arms 3:≥second-line therapy group, Number of participants experiencing clinical and laboratory adverse events (AEs), Approximately 40 months after the first participant is randomized
The purpose of this study is to evaluate the efficacy and safety of sintilimab+ IBI310 for EBV-Positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.